Lorabid Dosage

Generic name: loracarbef
Dosage form: Capsule, Suspension

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Lorabid is administered orally either at least 1 hour prior to eating or at least 2 hours after eating. The recommended dosages, durations of treatment, and applicable patient populations are described in the following chart:

DOSAGE Duration
POPULATION/INFECTION (mg) (days)
ADULTS (13 years and older)
 Lower Respiratory Tract
      Secondary Bacterial Infection of Acute Bronchitis 200–400 q12h 7
      Acute Bacterial Exacerbation of Chronic Bronchitis 400 q12h 7
      Pneumonia 400 q12h 14
 Upper Respiratory Tract
      Pharyngitis/Tonsillitis 200 q12h 10a
      Sinusitis 400 q12h 10
      (SeeCLINICAL STUDIESand INDICATIONS AND USAGE for further information.)
   Skin and Skin Structure
      Uncomplicated Skin and Skin Structure Infections 200 q12h 7
 Urinary Tract
      Uncomplicated cystitis 200 q24h 7
      (SeeCLINICAL STUDIESandINDICATIONS AND USAGE for further information.)
      Uncomplicated pyelonephritis 400 q12h 14
PEDIATRIC PATIENTS (6 months to 12 years)
 Upper Respiratory Tract
      Acute Otitis Mediab 30 mg/kg/day in 10
divided doses q12h
      (See CLINICAL STUDIESandINDICATIONS AND USAGE for further information.)
      Acute maxillary sinusitis 30 mg/kg/day in 10
divided doses q12h
      (See CLINICAL STUDIESandINDICATIONS AND USAGE for further information.)
      Pharyngitis/Tonsillitis 15 mg/kg/day in 10a
divided doses q12h
 Skin and Skin Structure
      Impetigo 15 mg/kg/day in 7
divided doses q12h
a In the treatment of infections due to S. pyogenes, Lorabid should be administered for at least 10 days.

b Otitis media should be treated with the suspension. Clinical studies of otitis media were conducted with the suspension formulation only. The suspension is more rapidly absorbed than the capsules, resulting in higher peak plasma concentrations when administered at the same dose. Therefore, the capsule should not be substituted for the suspension in the treatment of otitis media (seeCLINICAL PHARMACOLOGY).

PEDIATRIC DOSAGE CHART DAILY DOSE 15 mg/kg/day
100 mg/5 mL Suspension 200 mg/5 mL Suspension
Weight Dose given twice daily Dose given twice daily
lb kg mL tsp mL tsp
15 7 2.6 0.5
29 13 4.9 1.0 2.5 0.5
44 20 7.5 1.5 3.8 0.75
57 26 9.8 2.0 4.9 1.0
PEDIATRIC DOSAGE CHART DAILY DOSE 30 mg/kg/day
100 mg/5 mL Suspension 200 mg/5 mL Suspension
Weight Dose given twice daily Dose given twice daily
lb kg mL tsp mL tsp
15 7 5.2 1.0 2.6 0.5
29 13 9.8 2.0 4.9 1.0
44 20 7.5 1.5
57 26 9.8 2.0

Renal Impairment: Lorabid may be administered to patients with impaired renal function. The usual dose and schedule may be employed in patients with creatinine clearance levels of 50 mL/min or greater. Patients with creatinine clearance between 10 and 49 mL/min may be given half of the recommended dose at the usual dosage interval, or the normal recommended dose at twice the usual dosage interval. Patients with creatinine clearance levels less than 10 mL/min may be treated with the recommended dose given every 3 to 5 days; patients on hemodialysis should receive another dose following dialysis.

When only the serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance (CLcr, mL/min). The equation assumes the patient's renal function is stable.

(weight in kg) x (140 - age)
Males = (72) x serum creatinine (mg/100 mL)
Females = (0.85) x (above value)
Reconstitution Directions for Oral Suspension
Bottle Size Reconstitution Direction
100 mL Invert the bottle and tap to loosen powder. Add 60 mL of water in 2 portions to the dry mixture in the bottle.
Shake well after each addition.

After mixing, the suspension may be kept at room temperature, 15–30°C (59–86°F), for 14 days without significant loss of potency. Keep tightly closed. Discard unused portion after 14 days.

Hide
(web1)